Skip to main content

News

Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
12/21/2020
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index
DownloadPDF format download (opens in new window)
12/08/2020
Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock
DownloadPDF format download (opens in new window)
12/07/2020
Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock
DownloadPDF format download (opens in new window)
12/07/2020
Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update
DownloadPDF format download (opens in new window)
12/07/2020
Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
12/04/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
12/02/2020
Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020
DownloadPDF format download (opens in new window)
11/23/2020
Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting
DownloadPDF format download (opens in new window)
11/10/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
11/09/2020
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
DownloadPDF format download (opens in new window)
11/09/2020
Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer
DownloadPDF format download (opens in new window)
10/20/2020
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020
DownloadPDF format download (opens in new window)
10/19/2020
Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences
DownloadPDF format download (opens in new window)
10/14/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
09/24/2020
Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)
DownloadPDF format download (opens in new window)
09/22/2020
Marinus Announces One-for-Four Reverse Stock Split
DownloadPDF format download (opens in new window)
09/14/2020
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy
DownloadPDF format download (opens in new window)
09/14/2020
Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure
DownloadPDF format download (opens in new window)
09/08/2020
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
DownloadPDF format download (opens in new window)
08/11/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
08/06/2020
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
DownloadPDF format download (opens in new window)
07/30/2020
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)
DownloadPDF format download (opens in new window)
07/29/2020
Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors
DownloadPDF format download (opens in new window)
06/30/2020
Marinus Pharmaceuticals Provides Pipeline Update
DownloadPDF format download (opens in new window)
06/24/2020
Marinus Pharmaceuticals to Host Pipeline Update Webinar
DownloadPDF format download (opens in new window)
06/22/2020
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum
DownloadPDF format download (opens in new window)
06/16/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
06/15/2020
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary
DownloadPDF format download (opens in new window)
06/02/2020
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
DownloadPDF format download (opens in new window)
05/29/2020
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
DownloadPDF format download (opens in new window)
05/04/2020
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
DownloadPDF format download (opens in new window)
04/30/2020
Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board
DownloadPDF format download (opens in new window)
04/27/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
04/23/2020
Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020
DownloadPDF format download (opens in new window)
03/23/2020
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
DownloadPDF format download (opens in new window)
03/19/2020
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications
DownloadPDF format download (opens in new window)
03/16/2020
Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results
DownloadPDF format download (opens in new window)
02/25/2020
Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
02/24/2020
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
DownloadPDF format download (opens in new window)
02/14/2020
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
02/03/2020
Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
DownloadPDF format download (opens in new window)
01/13/2020
Marinus Provides Business Outlook for 2020
DownloadPDF format download (opens in new window)
01/07/2020
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
DownloadPDF format download (opens in new window)